166 related articles for article (PubMed ID: 38264503)
21. Determination of the Relationship Between Kobayashi, Sano, and Egami Criteria and Prevalence of Intravenous Immunoglobulin Resistance and Coronary Artery Aneurysm in Iranian Children with Kawasaki Disease.
Shashaani N; Shiari R; Karimi A; Salehi S; Ghanaei R; Hassas Yeganeh M; Shiari S; Rahmani K; Javadi Parvaneh V
Open Access Rheumatol; 2020; 12():187-192. PubMed ID: 32943952
[TBL] [Abstract][Full Text] [Related]
22. [Association of liver damage with coronary artery lesion and no response to intravenous immunoglobulin in the acute stage of Kawasaki disease].
Hu HM; Chen XZ; Zhang YL; DU ZD
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Jun; 24(6):681-686. PubMed ID: 35762436
[TBL] [Abstract][Full Text] [Related]
23. Corticosteroids for the treatment of Kawasaki disease in children.
Wardle AJ; Connolly GM; Seager MJ; Tulloh RM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011188. PubMed ID: 28129459
[TBL] [Abstract][Full Text] [Related]
24. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
25. Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.
Li W; Zhang L; Wang Z; He X; Lin H; Wang Y; Yuan J; Xie X; Zhang X; Qin Y; Huang P
Int J Clin Pract; 2022; 2022():2726686. PubMed ID: 35989868
[TBL] [Abstract][Full Text] [Related]
26. Neurological involvement in Kawasaki disease: a retrospective study.
Liu X; Zhou K; Hua Y; Wu M; Liu L; Shao S; Wang C
Pediatr Rheumatol Online J; 2020 Jul; 18(1):61. PubMed ID: 32664982
[TBL] [Abstract][Full Text] [Related]
27. Corticosteroid treatment of refractory Kawasaki disease.
Lang BA; Yeung RS; Oen KG; Malleson PN; Huber AM; Riley M; Ebbeson R; Ramsey SE; Laxer RM; Silverman ED; McCrindle BW; Ratnapalan S; Feldman BM
J Rheumatol; 2006 Apr; 33(4):803-9. PubMed ID: 16583481
[TBL] [Abstract][Full Text] [Related]
28. Recurrent Kawasaki disease at a tertiary care center in Chandigarh, North West India: 24 years of clinical experience.
Guleria S; Pilania RK; Jindal AK; Bhattarai D; Suri D; Singh S
Int J Rheum Dis; 2019 Jul; 22(7):1183-1187. PubMed ID: 30829007
[TBL] [Abstract][Full Text] [Related]
29. Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms.
Halyabar O; Friedman KG; Sundel RP; Baker AL; Chang MH; Gould PW; Newburger JW; Son MBF
Pediatr Rheumatol Online J; 2021 Mar; 19(1):31. PubMed ID: 33731148
[TBL] [Abstract][Full Text] [Related]
30. Refractory Kawasaki disease: modified methylprednisolone regimen decreases coronary artery dilatation.
Zhang M; Zheng Y; Li X; Yang S; Shi L; Li A; Liu Y
Pediatr Res; 2022 May; 91(6):1542-1550. PubMed ID: 34021270
[TBL] [Abstract][Full Text] [Related]
31. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology, clinical characteristics, and immediate outcome of Kawasaki disease: a population-based study from a tropical country.
Mat Bah MN; Alias EY; Razak H; Sapian MH; Foo FH; Abdullah N
Eur J Pediatr; 2021 Aug; 180(8):2599-2606. PubMed ID: 34086103
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
Liu J; Ye B; Su D; Qin S; Zhao W; Pang Y
Clin Rheumatol; 2023 Jan; 42(1):167-177. PubMed ID: 36129563
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Kawasaki Disease: A Single-Center Experience.
Uysal F; Bostan OM; Celebi S; Uysal B; Hamitoglu S; Cil E
Clin Pediatr (Phila); 2015 Jun; 54(6):579-84. PubMed ID: 25475592
[TBL] [Abstract][Full Text] [Related]
35. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
Kitoh T; Ohara T; Muto T; Okumura A; Baba R; Koizumi Y; Yamagishi Y; Mikamo H; Daigo K; Hamakubo T
Front Immunol; 2021; 12():624802. PubMed ID: 33912155
[TBL] [Abstract][Full Text] [Related]
36. Acute Appendicitis as the Initial Presentation of Kawasaki Disease Shock Syndrome in Children.
Chang YH; Lin CY; Liu LH; Huang FH; Cheng YJ
Children (Basel); 2022 Nov; 9(12):. PubMed ID: 36553263
[TBL] [Abstract][Full Text] [Related]
37. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
Li W; He X; Zhang L; Wang Z; Wang Y; Lin H; Yuan J; Xie X; Qin Y; Huang P
Cardiovasc Ther; 2021; 2021():6660407. PubMed ID: 34239607
[TBL] [Abstract][Full Text] [Related]
38. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S
Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920
[TBL] [Abstract][Full Text] [Related]
39. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
Han CL; Zhao SL
Med Sci Monit; 2018 Oct; 24():7264-7270. PubMed ID: 30307902
[TBL] [Abstract][Full Text] [Related]
40. Kawasaki Disease Associated Acute Abdomen: Most Require No Surgery.
She X; Chen J; Zhou YN; Guo J; Zhao FH; Yi C
J Inflamm Res; 2023; 16():5157-5162. PubMed ID: 38026259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
